Pulmonary Abnormalities in Liver Disease: Relevance to Transplantation and Outcome

Sarah Raevens, Maxine Boret, Michel De Pauw, Michael B. Fallon, Hans Van Vlierberghe

Research output: Contribution to journalReview articlepeer-review

Abstract

Pulmonary disease in liver cirrhosis and portal hypertension (PH) constitutes a challenging clinical scenario and may have important implications with regard to prognosis, liver transplantation (LT) candidacy, and post-LT outcome. Pre-LT evaluation should include adequate screening for pulmonary diseases that may occur concomitantly with liver disease as well as for those that may arise as a complication of end-stage liver disease and PH, given that either may jeopardize safe LT and successful outcome. It is key to discriminate those patients who would benefit from LT, especially pulmonary disorders that have been reported to resolve post-LT and are considered “pulmonary indications” for transplant, from those who are at increased mortality risk and in whom LT is contraindicated. In conclusion, in this article, we review the impact of several pulmonary disorders, including cystic fibrosis, alpha 1-antitrypsin deficiency, hereditary hemorrhagic telangiectasia, sarcoidosis, coronavirus disease 2019, asthma, chronic obstructive pulmonary disease, pulmonary nodules, interstitial lung disease, hepatic hydrothorax, hepatopulmonary syndrome, and portopulmonary hypertension, on post-LT survival, as well as the reciprocal impact of LT on the evolution of lung function.

Original languageEnglish (US)
JournalHepatology
DOIs
StateAccepted/In press - 2021

ASJC Scopus subject areas

  • Hepatology

Fingerprint

Dive into the research topics of 'Pulmonary Abnormalities in Liver Disease: Relevance to Transplantation and Outcome'. Together they form a unique fingerprint.

Cite this